Expertise in
11
conditions

Dr. Ingrid A. Mayer

Oncology | Hematology
Nashville, TN 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
11
conditions
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ingrid Mayer is an Oncologist and a Hematologist in Nashville, Tennessee. Dr. Mayer is highly rated in 11 conditions, according to our data. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Angiosarcoma, and HER-2 Positive Breast Cancer.

Her clinical research consists of co-authoring 155 peer reviewed articles and participating in 22 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in TN
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Nashville, TN 37232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Enrollment Status: Recruiting
Publish Date: August 06, 2025
Intervention Type: Drug
Study Drugs: Standard Therapy, AMG 386 +/- Trastuzumab, AMG 479 (Ganitumab)+Metformin, MK-2206 +/- Trastuzumab, AMG 386+Trastuzumab, T-DM1+Pertuzumab, Pertuzumab+Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 Cycle, Talazoparib+Irinotecan, Patritumab+Trastuzumab, Pembrolizumab - 8 Cycle, SGN-LIV1A, Durvalumab+Olaparib, SD-101+Pembrolizumab, Tucatinib+Trastuzumab and Pertuzumab, Cemiplimab, Cemiplimab+REGN3767, Trilaciclib +/- Trastuzumab+Pertuzumab, SYD985 ([vic-]Trastuzumab Duocarmazine), Oral Paclitaxel+Encequidar+Dostarlimab (TSR-042)+Carboplatin +/- Trastuzumab, Oral Paclitaxel+Encequidar+Dostarlimab (TSR-042) +/- Trastuzumab
Study Phase: Phase 2
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Enrollment Status: Recruiting
Publish Date: May 02, 2025
Intervention Type: Drug, Biological
Study Drugs: Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib, Utomilumab
Study Phase: Phase 2
A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer
A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: LEE011, Letrozole, BYL719
Study Phase: Phase 1/Phase 2
Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Fulvestrant, Avelumab
Study Phase: Phase 2
[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer
[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: F-18 16 Alpha-Fluoroestradiol
Study Phase: Phase 2
Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Drug, Other
Study Drugs: Alisertib, Fulvestrant
Study Phase: Phase 2
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drugs: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor
Study Phase: Phase 1
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2025
Intervention Type: Biological
Study Drug: Sacituzumab Govitecan
Study Phase: Phase 2
The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination With Pertuzumab in the Preoperative Setting
The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination With Pertuzumab in the Preoperative Setting
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2025
Intervention Type: Drug, Procedure
Study Drugs: T-DM1, Pertuzumab
Study Phase: Phase 2
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Drug
Study Drugs: LEE-011, Fulvestrant
Study Phase: Phase 2
A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)
A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)
Enrollment Status: Completed
Publish Date: November 14, 2024
Intervention Type: Drug
Study Drugs: Erdafitinib, Palbociclib, Fulvestrant
Study Phase: Phase 1
A Phase Ib Trial of BYL719 (an α-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
A Phase Ib Trial of BYL719 (an α-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2024
Intervention Type: Drug, Other
Study Drugs: PI3K inhibitor BYL719, Letrozole
Study Phase: Phase 1
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Pilot Trial of Ifetroban, A Thromboxane A2 Receptor Antagonist, in Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
A Pilot Trial of Ifetroban, A Thromboxane A2 Receptor Antagonist, in Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2024
Intervention Type: Drug, Other
Study Phase: Phase 2
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Enrollment Status: Withdrawn
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer Previously Exposed to Inhibitors of the PI3K Pathway: A Phase II Study With Pharmacodynamics Markers
Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer Previously Exposed to Inhibitors of the PI3K Pathway: A Phase II Study With Pharmacodynamics Markers
Enrollment Status: Completed
Publish Date: March 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
BRE 17107: A Phase Ib/II Trial of Atezolizumab (an Anti-PD-L1 Monoclonal Antibody) With Cobimetinib (a MEK1/2 Inhibitor) or Idasanutlin (an MDM2 Antagonist) in Metastatic ER+ Breast Cancer
BRE 17107: A Phase Ib/II Trial of Atezolizumab (an Anti-PD-L1 Monoclonal Antibody) With Cobimetinib (a MEK1/2 Inhibitor) or Idasanutlin (an MDM2 Antagonist) in Metastatic ER+ Breast Cancer
Enrollment Status: Terminated
Publish Date: August 11, 2021
Intervention Type: Drug
Study Drugs: Atezolizumab, Cobimetinib, Idasanutlin
Study Phase: Phase 1/Phase 2
Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 17, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 19 Less Clinical Trials

155 Total Publications

CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.
Journal: Future oncology (London, England)
Published: February 28, 2025
Similar Doctors
Expertise in
36
conditions
Dr. Adetola A. Kassim
Hematology | Oncology
Expertise in
36
conditions
Dr. Adetola A. Kassim
Hematology | Oncology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (2.1 miles away)
615-322-3000
Languages Spoken:
English, Yoruba
See accepted insurances
Accepting New Patients
Offers Telehealth

Adetola Kassim is a Hematologist and an Oncologist in Nashville, Tennessee. Dr. Kassim is highly rated in 36 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kassim is currently accepting new patients.

Expertise in
23
conditions
Dr. Erika Hamilton
Hematology | Oncology
Expertise in
23
conditions
Dr. Erika Hamilton
Hematology | Oncology

Verdi Oncology Tennessee PC

335 24th Ave N, Suite 200, 
Nashville, TN 
 (1.2 miles away)
615-284-2310
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Erika Hamilton is a Hematologist and an Oncologist in Nashville, Tennessee. Dr. Hamilton is highly rated in 23 conditions, according to our data. Her top areas of expertise are Breast Cancer, HER2 Negative Breast Cancer, Ovarian Cancer, and HER-2 Positive Breast Cancer.

Expertise in
17
conditions
Dr. Hans C. Lee
Hematology | Oncology
Expertise in
17
conditions
Dr. Hans C. Lee
Hematology | Oncology

Verdi Oncology Tennessee PC

335 24th Ave N, Suite 200, 
Nashville, TN 
 (1.2 miles away)
615-284-2310
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hans Lee is a Hematologist and an Oncologist in Nashville, Tennessee. Dr. Lee is highly rated in 17 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mayer's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile